VONOPRAZAN FUMARATE FOR THE TREATMENT OF STOMACH DISORDER: A REVIEW

 Stomach acid-related ailments, such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and Helicobacter Pylori getting ill, visible crucial clinical problems due to their prevalence and interest for major issues. Useful direction of these situations is vital for relief from symptoms, mucosal healing, and avoidance of complications. The purpose of this study is to compare vonoprazan, a new potassium-competitive acid blocker (P-CAB), with more established proton pump inhibitors (PPIs) in terms of effectiveness and safety for treating disorders linked to stomach acid. A thorough evaluation of research and clinical trials was done to determine how well vonoprazan worked in treating Helicobacter Pylori infection, GERD, and PUD. In addition, vonoprazan's safety record was examined, and similarities with PPIs as well as other stomach acid suppressants were drawn. Compared to PPIs, vonoprazan exhibits greater and more reliable acid suppression, which leads to quick and long-lasting symptom alleviation and mucosal repair. Clinical trials have demonstrated its effectiveness in treating Helicobacter Pylori infection, GERD, and PUD. When combined with other medications, the rate of Helicobacter Pylori eradication is greater. Compared to PPIs, vonoprazan has a better safety profile with fewer side effects and medication interactions. Vonoprazan presents a viable substitute for conventional proton pump inhibitors in the treatment of disorders associated with stomach acid. For patients in need of dependable and efficient acid suppression, its distinct mode of action and enhanced effectiveness render it a highly advantageous choice. To establish long-term safety data and investigate its potential in larger therapeutic applications, more study is necessary.